Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors

Zhiyang Li; Xin Wu; Yanjie Zhao; Yinan Xiao; Yunuo Zhao; Ting Zhang; Hui Li; Fushen Sha; Yating Wang; Lei Deng; Xuelei Ma

doi:10.1002/mco2.61

Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors

MedComm (2020). 2021 Mar 11;2(1):60-68. doi: 10.1002/mco2.61. eCollection 2021 Mar.

Authors

Zhiyang Li^{1

2}, Xin Wu³, Yanjie Zhao^{1

2}, Yinan Xiao^{1

4}, Yunuo Zhao^{1

4}, Ting Zhang^{1

2}, Hui Li^{1

2}, Fushen Sha⁵, Yating Wang⁶, Lei Deng⁷, Xuelei Ma^{1

4}

Affiliations

¹ Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu Sichuan China.
² West China Hospital, West China School of Medicine Sichuan University Chengdu Sichuan China.
³ Head and Neck Carcinoma Department, Radiation Oncology Department, Cancer Center West China Hospital Chengdu Sichuan China.
⁴ State Key Laboratory of Biotherapy Department of Biotherapy, West China Hospital, Cancer Center Sichuan University Chengdu Sichuan China.
⁵ Department of Internal Medicine State University of New York: Downstate Medical Center Brooklyn New York USA.
⁶ Department of Internal Medicine Louis A. Weiss Memorial Hospital Chicago Illinois USA.
⁷ Jacobi Medical Center Albert Einstein College of Medicine, Bronx New York New York USA.

PMID: 34766136
PMCID: PMC8491227
DOI: 10.1002/mco2.61

Abstract

PD-1/PD-L1 (programmed cell death-1 and programmed death-ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti-PD-1/PD-L1 therapy. A comprehensive search was conducted in electronic databases to identify eligible studies. Major response rate (MRR) and complete response rate (CRR) were pooled in this analysis to assess the efficacy of neoadjuvant anti-PD-1/PD-L1 utilization, all grades and high-grade adverse events (AEs) were pooled to evaluate its safety. Twenty studies were included in this meta-analysis, with 828 patients suffering from different tumors. The pooled CRR of triple-negative breast cancer was 0.569 (95% CI 0.514, 0.624, I ² = 0%) and the pooled MRR of lung cancer was 0.471 (95% CI 0.267, 0.575, I ² = 0%). The most frequent adverse event was fatigue (0.272 95% CI 0.171, 0.402, I ² = 87%), and the most common high-grade adverse event was febrile neutropenia (0.084 95% CI 0.063, 0.112, I ² = 85%). In conclusion, neoadjuvant anti-PD-1/PD-L1 therapy received satisfactory clinical results in these tumors included.

Keywords: PD‐1/PD‐L1 inhibitors; atezolizumab; lung cancer; neoadjuavant therapy; triple‐negative breast cancer.